Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2-positive metastatic breast cancer: A phase II trial.

Qiao Li, Zijing Wang, Maiyue He et al.|Journal of Clinical Oncology|2023

Cited by 3